Drug Profile
Research programme: lobeline analogues - Yaupon Therapeutics
Alternative Names: LobelaneLatest Information Update: 12 Jan 2012
Price :
$50
*
At a glance
- Originator Yaupon Therapeutics
- Developer Ceptaris Therapeutics
- Class
- Mechanism of Action Vesicular monoamine transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Substance-related disorders
Most Recent Events
- 08 Jan 2012 Discontinued - Preclinical for Substance-related disorders in USA (unspecified route)
- 07 Nov 2007 Preclinical trials in Substance-related disorders in USA (unspecified route)